VEGFC and neoplasm: Moreover, tumor-associated lymphangiogenesis may serve as one of the novel therapeutic targets of ICC, of which the VEGF-C/VEGF-D-VEGFR3 axis is considered a major driver of tumor-associated lymphangiogenesis [33].